Lawyers refute witness’s testimony in trial over Kyobo’s dispute with investors Kyobo Life vice president, key witness in case, recants part of his previous statements
Translated by Ryu Ho-joung 공개 2021-10-20 08:10:52
이 기사는 2021년 10월 20일 08:08 thebell 에 표출된 기사입니다.
Lawyers representing individuals from Deloitte Anjin and the investor consortium, who were indicted by South Korean prosecutors earlier this year for allegedly mispricing shares of Kyobo Life Insurance, refuted a key witness in the fourth trial on Friday, leading him to recant some of his earlier testimony.Lawyers for the defendants submitted additional email evidence and continued to cross-examine Park Jin-ho, Kyobo’s vice president, in the fourth trial over the dispute between Shin Chang-jae, Kyobo’s chairman, and its financial investors.
At issue in the case is whether the investor consortium, led by Affinity Equity Partners, played a leading role in creating Deloitte Anjin’s valuation report on Kyobo shares, as the insurance company argues.
Park previously contended that Deloitte Anjin did not perform the valuation in an objective manner, but just carried out calculations according to the investors’ directions, citing emails exchanged between the investor consortium and the accounting firm as evidence.
However, during his cross-examination by lawyers for the defendants in the latest trial, Park agreed that the investor consortium did not instruct Deloitte Anjin on either the date on which the valuation was based or which valuation method to use, the key issues in the second and third trials of the case.
Lawyers for the defendants also set forth standard contracts used by the four biggest accounting firms to refute Park’s earlier claim that a scope of losses covered by the indemnification agreement between Deloitte Anjin and the investor consortium was exceptionally broad. This made him recant his earlier statements.
In 2012 the investor consortium, which includes Affinity Equity Partners, IMM Private Equity, Baring Private Equity Asia and Singapore’s GIC, purchased a combined 24% of the insurance company for approximately 1.2 trillion won ($1 billion), with put options enabling them to sell their stakes to Shin if it failed to go public by 2015.
Kyobo remained as a private company beyond the deadline, prompting the investors to exercise the put options in October 2018 to sell their shares at 409,000 won per share, or nearly 2 trillion won in total, based on a valuation performed by Deloitte Anjin.
Shin refused to fulfill the agreement and Kyobo reported the accounting firm and the investors for allegedly conspiring to misprice shares subject to the put options. Prosecutors indicted three accountants from Deloitte Anjin and two officials from Affinity Equity and IMM PE in January this year. The fifth trial is scheduled for October 29. (Reporting by Ha-na Suh)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- '재무개선' AJ네트웍스, 조달비용 '확' 낮췄다
- '9년만에 엑시트' 한앤코, 한온시스템 거래구조 살펴보니
- 한국타이어앤테크놀로지, 한온시스템 인수한다
- [수술대 오른 커넥트웨이브]2대주주 지분매입 나선 MBK, 주식교환 카드 꺼냈다
- [이사회 모니터]이재용 에이비프로바이오 대표, 바이오·반도체 신사업 '드라이브'
- 와이투솔루션, 주인 바뀌어도 '신약' 중심엔 美 합작사 '룩사'
- 아이티센, 부산디지털자산거래소 본격 출범
- 아이에스시, AI·데이터센터 수주 증가에 '날개'
- [이사회 모니터]서정학 IBK증권 대표, ESG위원회도 참여 '영향력 확대'
- SW클라우드 '10주년' 폴라리스오피스, “초격차 밸류업”